Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The entry "novel transcript, antisense to ZNF24" (ENSG00000308423) refers to an annotated transcript described as antisense to the protein-coding gene *Zinc finger protein 24* (ZNF24). Unlike ZNF24, which codes for a transcription factor involved in oligodendrocyte myelination and tumor suppression[1][2][5][6], there is no functional, mechanistic, or clinical information available for this antisense transcript in major gene or biomedical databases. It is not recognized as a receptor, enzyme, transporter, therapeutic target, or biomarker. This suggests the entry is either not biologically validated, not of therapeutic interest, or an artifact from transcriptome annotation pipelines. Caveat: - There is extensive literature and data on *ZNF24 (Zinc finger protein 24)* itself[1][2][5][6], but nothing directly supports the therapeutic relevance, clinical use, or clear molecular function of an antisense transcript to ZNF24. - The use of an Ensembl ID in the ENSG00000308xxx range is highly atypical for known, protein-coding, functional targets (e.g., *ZNF24* is ENSG00000172466[5]), further substantiating that this entry may refer to a predicted, low-confidence transcript[5]. Summary: The given target is not a recognized therapeutic target; there is likely a data entry issue or an annotation describing an uncharacterized transcript. All functional and disease information pertains to *ZNF24*, not to this antisense entity[1][2][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on novel transcript, antisense to Zinc finger protein 24.